CD33 and acute myeloid leukemia: The CD33 antibody–drug conjugate gemtuzumab ozogamicin was the only approved antibody-targeted therapy for AML, and the CD33/CD3-bispecific BiTE antibody construct has shown potent pre-clinical anti-AML activity (152).